Financial Gravity Companies’s PDL BioPharma, Inc. PDLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$0 Buy
+13
New ﹤0.01% 1020
2025
Q2
$3 Buy
+33
New +$3 ﹤0.01% 979
2024
Q4
$0 Buy
+32
New ﹤0.01% 1029
2018
Q4
$0 Buy
+153
New +$420 ﹤0.01% 1601
2018
Q1
$1K Sell
229
-12,767
-98% -$34.8K ﹤0.01% 1364
2017
Q4
$36K Buy
+12,996
New +$39.9K 0.04% 389

Other funds holding PDLI

Financial Gravity Companies's PDLI Position: Q2 2026 in Review

Financial Gravity Companies opened a new position in PDL BioPharma, Inc. (PDLI) in Q2 2026: 13 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1020 among its holdings. This is a return to the name: Financial Gravity Companies previously reported a position in PDLI as recently as Q2 2025.

Financial Gravity Companies first reported a position in PDLI in Q4 2017 and has held it in 6 quarters since. The position peaked at $36K in Q4 2017. 5 funds tracked by Wall St. Rank hold PDLI as of Q2 2026.

  • Financial Gravity Companies held 13 shares of PDL BioPharma, Inc. worth $0 as of Q2 2026.
  • PDL BioPharma, Inc. was a new Financial Gravity Companies position in Q2 2026.
  • PDL BioPharma, Inc. made up ﹤0.01% of Financial Gravity Companies's portfolio in Q2 2026, its #1020 holding.
  • Financial Gravity Companies first reported a position in PDL BioPharma, Inc. in Q4 2017 and has held it in 6 quarters since.
  • Financial Gravity Companies's PDL BioPharma, Inc. position peaked at $36K in Q4 2017.
  • 5 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2026.

Based on Financial Gravity Companies's 13F filing for Q2 2026, filed 5 Aug 2026.